TrialESMO open2026

Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from the phase II nITRO trial.

E Scarlato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.